Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Cannabis increases the concentrations of which medication in adolescents?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 203 - 222Publisher: Cambridge University PressPrint publication year: 2023
References
Babson, K. A., Sottile, J., Morabito, D. Cannabis, , cannabinoids and sleep: a review of the literature. Curr Psychiatry Rep 2017; 19(4): 23. https://doi.org/10.1007/s11920-017-0775-9Google Scholar
Bloomfield, M. A. P., Ashok, A. H., Volkow, N. D., et al. The effects of δ9-tetrahydrocannabinol on the dopamine system. Nature 2016; 539(7629): 369–77. https://doi.org/10.1038/nature20153Google Scholar
Bloomfield, M. A. P., Morgan, C. J. A., Kapur, S., et al. The link between dopamine function and apathy in cannabis users: an [18 F]-DOPA PET imaging study. Psychopharmacology (Berl) 2014; 231(11): 2251–59. https://doi.org/10.1007/s00213-014-3523-4Google Scholar
Cascini, F., Aiello, C., Di Tanna, G. Increasing delta-9-tetrahydrocannabinol (δ -9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5(1): 32–40. https://doi.org/10.2174/1874473711205010032Google Scholar
Ceccarini, J., Koole, M., Van Laere, K. Cannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: a preliminary multitracer positron emission tomography study. Addict Biol 2022; 27(3): e13167. https://doi.org/10.1111/adb.13167Google Scholar
Desrosiers, N. A., Himes, S. K., Scheidweiler, K. B., et al. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 2014; 60(4): 631–43. https://doi.org/10.1373/clinchem.2013.216507Google Scholar
Foley, K. F., DeSanty, K. P., Kast, R. E. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006; 6(9): 1249–65. https://doi.org/10.1586/14737175.6.9.1249Google Scholar
Gray, K. M., Carpenter, M. J., Baker, N. L., et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012; 169(8): 805–12. https://doi.org/10.1176/appi.ajp.2012.12010055CrossRefGoogle ScholarPubMed
Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42(4): 327–60. https://doi.org/10.2165/00003088-200342040-00003CrossRefGoogle ScholarPubMed
Hill, M. N., Sun, J. C., Tse, M. T. L., et al. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol 2006; 9(3): 277–86. https://doi.org/10.1017/S1461145705005651Google Scholar
Incze, M. A., Kelley, A. T., Singer, P. M. Heterogeneous state cannabis policies: potential implications for patients and health care professionals. JAMA 2021; 326(23): 2363–64. https://doi.org/10.1001/jama.2021.21182Google Scholar
Pertwee, R. G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153(2): 199–215. https://doi.org/10.1038/sj.bjp.0707442Google Scholar
Silins, E., Horwood, L. J., Patton, G. C., et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 2014; 1(4): 286–93. https://doi.org/10.1016/S2215-0366(14)70307-4Google Scholar
Strougo, A., Zuurman, L., Roy, C., et al. Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate: insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J Psychopharmacol 2008; 22(7): 717–26. https://doi.org/10.1177/0269881108089870Google Scholar
Vaughn, S. E., Strawn, J. R., Poweleit, E. A., et al. The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations. J Pers Med 2021a; 11(7): 615. https://doi.org/10.3390/jpm11070615Google Scholar
Weinberger, A. H., Zhu, J., Lee, J., et al. Cannabis use among youth in the United States, 2004–2016: faster rate of increase among youth with depression. Drug Alcohol Depend 2020; 209: 107894. https://doi.org/10.1016/j.drugalcdep.2020.107894CrossRefGoogle ScholarPubMed
Zuurman, L., Ippel, A. E., Moin, E., et al. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009; 67(1): 5–21. https://doi.org/10.1111/j.1365-2125.2008.03329.xGoogle Scholar